library.onepin.app/klow-blend Peptide Education Library
Education only, not medical advice 21+ Every dose is an example to finalize with a licensed provider

OnePin Peptide Library · Repair & Recovery

Repair & Recovery Pre-mixed repair and anti-inflammatory blend Not FDA-approved · investigational

Klow Blend

Klow · Klow Stack

Pre-mixed repair and anti-inflammatory blendGHK-Cu + KPV + BPC-157 + TB-500 combinationCollagen remodelingNF-kB anti-inflammatory

The Klow Blend is a four-peptide repair and anti-inflammatory combination containing GHK-Cu (50mg), KPV (10mg), BPC-157 (10mg), and TB-500 (10mg). It builds on the Glow Blend by adding KPV, a tripeptide derived from alpha-MSH that provides targeted NF-kB anti-inflammatory signaling. The name is a portmanteau of KPV and Glow. This is the most comprehensive single-vial repair blend available, addressing angiogenesis, cell migration, collagen remodeling, and upstream inflammatory pathway suppression.

Quick Start
Route
SubQ injection. DRAW LAST when combining with other peptides.
Start low
Per compound concentrations in vial (typically 0.5-1mg GHK-Cu + 100-500mcg KPV + 100-500mcg BPC + 100-500mcg TB per injection)
Frequency
Daily or 5 days on / 2 days off
Timing
No fasting required

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first
Quick Start
Conservative start
Per compound concentrations in vial (typically 0.5-1mg GHK-Cu + 100-500mcg KPV + 100-500mcg BPC + 100-500mcg TB per injection) · SubQ injection. DRAW LAST when combining with other peptides. · Daily or 5 days on / 2 days off
Lowest starting point. Hold about a week to assess tolerance before stepping up.
Per compound concentrations in vial (typically 0.5-1mg GHK-Cu + 100-500mcg KPV + 100-500mcg BPC + 100-500mcg TB per injection)
Daily or 5 days on / 2 days off
Intermediate
Anti-Inflammatory Glow
1.5-2 mg total · SubQ · Daily
anecdotal · community
1.5-2 mg total
Daily
Reconstitution CalculatorU-100
050100u
Draw to
units
01

How it works

The Klow Blend combines four distinct and complementary mechanisms that together address the full healing cascade from inflammation suppression through structural remodeling:

The Klow Blend combines four distinct and complementary mechanisms that together address the full healing cascade from inflammation suppression through structural remodeling:

GHK-Cu Component (50mg): Delivers copper(II) to lysyl oxidase for collagen cross-linking and extracellular matrix integrity. Modulates approximately 4,000 genes involved in tissue repair, upregulating collagen, decorin, and metalloproteinases while suppressing tissue destruction genes. Stimulates synthesis of collagen types I, III, and V, elastin, and glycosaminoglycans. Regulates copper-dependent antioxidant enzymes.

KPV Component (10mg): Suppresses the NF-kB inflammatory signaling cascade by preventing nuclear translocation of NF-kB p65 subunit, reducing transcription of pro-inflammatory cytokines IL-1beta, IL-6, IL-8, and TNF-alpha. Unlike NSAIDs (COX inhibitors) or corticosteroids (broad immune suppression), KPV targets upstream NF-kB signaling for more specific anti-inflammatory action. Accumulates at sites of mucosal inflammation, making it particularly effective for GI applications.

BPC-157 Component (10mg): Activates local repair through VEGF-driven angiogenesis, NO system modulation, GH receptor upregulation, and FAK-paxillin cell migration pathway activation. Creates the vascular infrastructure for tissue repair.

TB-500 Component (10mg): Drives systemic repair via actin polymerization regulation, enabling repair cell migration to injury sites throughout the body. Suppresses NF-kB signaling through a pathway complementary to KPV.

Synergy: KPV and TB-500 both suppress NF-kB but through different mechanisms, providing redundant anti-inflammatory coverage. BPC-157 builds the vascular network, TB-500 delivers the repair cells, GHK-Cu provides the collagen remodeling template, and KPV ensures inflammation does not impede any of these processes.

02

What to expect

Early
Days 1–7

Days 1-7: KPV begins suppressing NF-kB inflammatory cytokines. BPC-157 and TB-500 reduce local inflammation and pain. GHK-Cu starts gene expression modulation. Gut-targeted users may notice early GI comfort from KPV + BPC-157 combination. Blue tint of reconstituted solution is normal (copper).

Mid
Weeks 2–4

Weeks 2-4: KPV anti-inflammatory effects fully established. GHK-Cu collagen synthesis producing visible skin improvements. BPC-157 angiogenesis and TB-500 cell migration driving measurable healing. Gut inflammation substantially reduced. Chronic injuries responding.

Later
Weeks 4–12

Weeks 4-12: Full four-pathway repair consolidation. GHK-Cu collagen remodeling at peak effect. KPV maintaining low inflammatory baseline. Structural tissue repair from BPC/TB nearing completion. Chronic issues with inflammatory component showing best results due to KPV + TB-500 dual NF-kB suppression.

03

Evidence

HumanNo published trials
AnimalStrong
In-vitroPresent
2008PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation · Dalmasso G et al, Gastroenterology ↗peer reviewed
2018Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data · Pickart L, Margolina A, International Journal of Molecular Sciences ↗review
2015GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration · Pickart L et al, BioMed Research International ↗review
2008Melanocortin-derived tripeptide KPV has anti-inflammatory effects · Kannengiesser K et al, Inflammatory Bowel Diseases ↗peer reviewed
04

The honest take

Most comprehensive single-vial repair blend available

Factually accurate in terms of number of distinct mechanisms covered (angiogenesis, cell migration, collagen remodeling, NF-kB suppression). However, 'comprehensive' does not mean proven superior to simpler combinations.

KPV targets upstream NF-kB more specifically than NSAIDs

Mechanistically distinct from NSAIDs (COX inhibitors) - KPV acts on NF-kB nuclear translocation rather than prostaglandin synthesis. Whether this is clinically 'better' has not been tested in human comparative studies.

KPV + BPC-157 synergy for gut healing
Plausible

Plausible - KPV reduces mucosal inflammation via NF-kB while BPC-157 promotes mucosal repair via VEGF/NO pathways. Both show gut-protective effects in animal models, but the combination has not been studied.

05

Interactions & stacking

What's safe to combine, and what belongs in a separate pin.

Safe & synergistic

AOD-9604No interaction. Safe to draw into same syringe. Draw Klow LAST.
IpamorelinIpa His minimal chelation in seconds. Draw Klow LAST.
MOTS-cSafe in same syringe. Draw Klow LAST.
SelankNo reactive residues. Safe in same syringe. Draw Klow LAST.

Keep separate

VIPCopper oxidizes VIP Met-17 even during brief syringe contact. VIP is hyper-sensitive to copper. Hard stop.
LL-37BPC-157 is anionic. LL-37 is cationic (+6 charge). Charge interaction causes aggregation.
OxytocinCysteine disulfide bond in oxytocin is reactive with copper. Do not mix.
CJC-1295 with DACDAC maleimide linker reacts with peptides. Pin CJC-DAC separately.
06

Side effects & safety

Commonly reported

  • Mild injection site redness or warmth (resolves in minutes)
  • Temporary skin flushing from copper component
  • Occasional lightheadedness post-injection
  • Mild GI changes during gut healing (temporary, from KPV + BPC activity)

Less common & notes

  • Rarely reported: headache, transient nausea, mild metallic taste, localized copper skin staining (cosmetic, fades).
  • KPV is derived from alpha-MSH but lacks melanogenic activity at therapeutic doses - it should not cause skin darkening.
  • All four components have favorable safety profiles in preclinical studies, but long-term human safety data for the injectable combination does not exist.
07

Pharmacokinetics

Illustrative plasma concentration · 24 h
Half-life
GHK-Cu: ~1 hour; KPV: ~30 min; BPC-157: ~2 min (rapid distribution); TB-500: ~2-3 hours
Peak · Tmax
GHK-Cu: ~30 min; KPV: ~15-30 min; BPC-157: minutes (local); TB-500: 1-2 hours
Elimination
GHK-Cu: ~6 hours; KPV: ~3-4 hours; BPC-157: ~20 hours (activity); TB-500: ~12-16 hours
Activity
GHK-Cu: 12-24 hours (gene expression); KPV: 12-24 hours (NF-kB suppression persists); BPC-157: 12-24 hours (VEGF/eNOS); TB-500: 24-48 hours (actin effects)

Storage. Reconstitute with bacteriostatic water. Store refrigerated at 2-8 degrees C. Blue tint from copper ion is normal and does not indicate degradation. Shelf life approximately 28 days after reconstitution. Do not freeze after reconstitution. Protect from prolonged light exposure. Discard if cloudy, particulate, or color changes beyond normal blue tint.

08

Regulatory status

Not FDA-approved. Available through compounding pharmacies with prescription in some jurisdictions and through research chemical suppliers. Contains four research peptides. GHK-Cu has published human topical data. BPC-157 has FDA Orphan Drug Designation. KPV has preclinical anti-inflammatory data. All current human use is experimental and off-label.

Put it to work

Calculate, log & track

Open Klow Blend straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open Klow Blend in the app →

Go deeper

The guide & community

The complete Klow Blend walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗
Open in app Community